ClinicalTrials.gg
CompletedNCT02027428Updated Aug 17, 2020Results posted

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

A Phase 3 interventional study of Abraxane (Induction) and Carboplatin (Induction) in Squamous Cell Carcinoma, Non-Small-Cell Lung, sponsored by Celgene. Completed at 119 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-17.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Carcinoma, Squamous Cell with a site in United States — 68 open to participants now, 99 under way, 6 of them phase 3. Carcinoma, Squamous Cell · United States.

Enrollment
22nd of 280
427 · median 37
Started
2014
with 16 others
Phase 3
24 of 330
3 open now
Registered
126th of 330
by date

Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, this one is the 22nd largest by enrollment of the 280 interventional ones that give a count, is one of 17 that started in 2014, is one of 24 in phase 3, and was the 126th registered.

Carcinoma, Squamous Cell

628 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

68 of the 330 studies in Carcinoma, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Carcinoma, Squamous Cell with a site in United States, or all of them as a file.
02

Study summary

Maintenance treatment of advanced stage squamous cell NSCLC.

Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin as induction in subjects with stage IIIB/IV squamous cell NSCLC.

Subjects who discontinued treatment from the maintenance part for any reason other than withdrawal of consent, lost to follow-up, or death, were entered into a Follow-up period that had a visit 28 days after progression or discontinuation.

Those who entered Follow-up without progression continued with follow-up scans according to standard of care (SOC) until documentation of progression of disease. Additionally, subjects were followed for OS by phone approximately every 90 days for a minimum of 18 months, for up to approximately 5 years after the last subject was randomized.

Read the detailed description

The sponsor used 15 Sep 2017 as the database cut-off date.

03

Conditions studied

  • Squamous Cell Carcinoma, Non-Small-Cell Lung

Keywords

  • Nab-paclitaxel
  • Albumin bound paclitaxel
  • Taxanes
  • Maintenance trials
  • Celgene
  • Abraxane
  • ABI-007
  • NSCLC
  • Non-Small Cell Lung Cancer
  • Cancer of the Lung
  • Carcinoma, Squamous Cell
  • Lung Neoplasms
  • Abound.sqm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years of age at the time of signing the Form.
  2. Understand and voluntarily provide written consent to the Informed Consent Form prior to conducting any study related assessments/procedures.
  3. Able to adhere to the study visit schedule and other protocol requirements

    Disease Specific

  4. or cytologically confirmed Stage IIIB or IV squamous cell Non Small Cell Lung Cancer at study entry.
  5. No other current active requiring anticancer therapy.
  6. Radiographically documented at study entry (as defined by the [RECIST] v1.1 criteria).
  7. No prior chemotherapy for the treatment of disease at study entry. chemotherapy is permitted providing cytotoxic chemotherapy was completed 12 months prior to starting the study and without disease recurrence.
  8. ≥ 1500 cells/mm\^3.
  9. ≥ 100,000 cells/mm\^3.
  10. ≥ 9 g/dL.
  11. /serum glutamic oxaloacetic transaminase, alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × or ≤ 5.0 × upper limit of normal range if liver metastases.
  12. Total ≤ 1.5 × upper limit of normal range except in cases of Gilbert's disease and liver metastases.
  13. Creatinine ≤ 1.5 mg/dL.
  14. Expected survival of > 12 weeks for the Induction part of the study.
  15. (ECOG) performance status 0 or 1.
  16. For Maintenance part of the study, subjects must have received at least one dose of nab-paclitaxel in each of the 4 cycles during Induction

    Pregnancy

  17. Females of [defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:

    1. agree to take a pregnancy test prior to starting study medication and throughout the study participation.
    2. commit to complete abstinence from heterosexual contact, or agree to use medical doctor-approved throughout the study without interruption, and while receiving study medication or for a longer period if required by local regulations.
  18. Male subjects must:

    c. agree to complete abstinence from heterosexual contact or use a condom during sexual contact with a female of child bearing potential while receiving study medication and within 6 months after last dose of study medication, even if he has undergone a successful vasectomy.

  19. Females must abstain from breastfeeding during study participation and 3 months after IP discontinuation.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment into the Induction and Maintenance parts of the study (except if specified at study entry only):

  1. Evidence of active , including (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for ≥ 4 weeks prior to first dose of study drug).
  2. Only evidence of disease is non-measurable at study entry.
  3. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per v4.0).
  4. Venous thromboembolism within 6 months prior to signing Form.
  5. Current congestive heart failure ( class II-IV).
  6. History of the following within 6 months prior to first administration of a study drug: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, cardiac dysrhythmia or clinically significant (ECG) abnormality, cerebrovascular accident, , or seizure disorder.
  7. Treatment with any product within 28 days prior to signing Informed Consent Form.
  8. History of allergy or to nab-paclitaxel or carboplatin.
  9. Currently enrolled in any other clinical protocol or investigational trial that involved administration of experimental therapy and/or therapeutic devices.
  10. Any other clinically significant medical condition and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol.
  11. Subject has any other within 5 years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of T1a or T1b) - all treatments that should have been completed 6 months prior to signing informed consent form (ICF).
  12. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting investigational product (IP), and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
  13. Pregnant and nursing females.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
427 participants (actual)

Study arms

  • Experimental
    Abraxane + Best Supportive Care (BSC)

    Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.

    Drug: Abraxane (Induction) · Drug: Carboplatin (Induction) · Drug: Abraxane (Maintenance) · Other: Best Supportive Care (Maintenance)

  • Other
    Best Supportive Care (BSC)

    Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.

    Drug: Abraxane (Induction) · Drug: Carboplatin (Induction) · Other: Best Supportive Care (Maintenance)

Interventions

  • 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care

    Also known as: nab-paclitaxel

  • 6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion

  • 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care

  • OtherBest Supportive Care (Maintenance)

    The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents

  • 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care

    Also known as: nab-paclitaxel

  • 6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care

  • OtherBest Supportive Care (Maintenance)

    The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance

    Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography \[CT scan\], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions.

    Time frame: From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months

Secondary outcomes

  1. Kaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance

    Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.

    Time frame: From the date of randomization to death from any cause; up to 01 August 2019; survival follow up was 55.89 months

  2. Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study

    Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline.

    Time frame: Day 1 of treatment in the induction period and subsequent anticancer therapy, death or discontinuation up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study

  3. Kaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study

    PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression.

    Time frame: Between Day 1 of the Induction Part through to the date of disease progression or death; up to 01 August 2019; the maximum treatment duration was 234.1 weeks for entire study

  4. Kaplan-Meier Estimate of Overall Survival (OS) Over Entire Study

    Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.

    Time frame: Between Day 1 of treatment in the Induction Part to death from any cause; up to 01 August 2019; survival follow up was 55.89 months

  5. Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction

    Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease.

    Time frame: For the induction period the maximum treatment was 19 weeks for the maintenance period the maximum treatment was 150 weeks.

  6. Percentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study

    Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for \>= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method.

    Time frame: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 induction through maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study

  7. Time to Confirmed Response During Induction and Over the Entire Study

    Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary.

    Time frame: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 Induction through Maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study

  8. Kaplan-Meier Estimate for Duration of Response Over the Entire Study

    Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death.

    Time frame: Between Day 1 of the Induction Period through to the date of disease progression or death; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study.

  9. Participants With Treatment-Emergent Adverse Events (TEAEs) in the Induction Period

    TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.

    Time frame: Day 1 of Induction up to Week 23 (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance)

  10. Participants With Treatment-Emergent Adverse Events (TEAEs) Over the Entire Study

    TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.

    Time frame: From Day 1 up to 01 August 2019; (maximum treatment length plus 28 days); the maximum treatment duration was 234.1 weeks for entire study

07

Results

Posted Dec 7, 2018

Participant flow

The study was conducted at 87 sites in Germany, Italy, Spain, the United Kingdom and the United States.

Induction
Participant flow — Induction
MilestoneAll Participants - InductionNab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)
Started42700
Received study drug42000
Completed20200
Not completed22500
Withdrew: Never treated700
Withdrew: Progressive disease7700
Withdrew: Adverse event5100
Withdrew: Withdrawal by subject2200
Withdrew: Death2100
Withdrew: Symptomatic deterioration1600
Withdrew: Study terminated by sponsor1200
Withdrew: Protocol violation100
Withdrew: Miscellaneous1400
Withdrew: Induction treatment ongoing400
Maintenance
Participant flow — Maintenance
MilestoneAll Participants - InductionNab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)
Started013666
Completed0126
Not completed012460
Withdrew: Death032
Withdrew: Adverse event0211
Withdrew: Progressive disease08447
Withdrew: Symptomatic deterioration041
Withdrew: Withdrawal by subject065
Withdrew: Protocol violation001
Withdrew: Other063
Survival Follow-up
Participant flow — Survival Follow-up
MilestoneAll Participants - InductionNab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)
Started011755
Completed0389
Not completed07946
Withdrew: Death07845
Withdrew: Lost to follow-up011

Outcome measures

PrimaryKaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance

Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography \[CT scan\], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions.

Time frame:
From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months
Reported as:
Median · months
Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance
monthsNab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)
Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance3.12 (2.73 to 4.60)2.60 (1.64 to 3.45)
Statistical analysis
  • Nab-Paclitaxel + Best Supportive Care (BSC) vs Best Supportive Care (BSC) · stratified log-rank test · p = 0.3486 (Stratification factors evaluated in the sparse strata elimination algorithm: stage of disease (IIIB or IV) at diagnosis, ECOG performance status (0 or 1) at end of Induction, and tumor response (CR/PR or SD) at end of Induction.) · Hazard ratio (hr): 0.85 · 95% CI 0.61 to 1.19Hazard ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryKaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance

Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.

Time frame:
From the date of randomization to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
Reported as:
Median · months
Kaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance
monthsNab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)
Kaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance17.61 (13.86 to 21.09)12.16 (7.56 to 18.99)
Statistical analysis
  • Nab-Paclitaxel + Best Supportive Care (BSC) vs Best Supportive Care (BSC) · stratified log-rank test · p = 0.0365 (Stratification factors evaluated in the sparse strata elimination algorithm: stage of disease (IIIB or IV) at diagnosis, ECOG performance status (0 or 1) at end of Induction, and tumor response (CR/PR or SD) at end of Induction.) · Hazard ratio (hr): 0.68 · 95% CI 0.47 to 0.98Hazard ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryPercentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study

Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline.

Time frame:
Day 1 of treatment in the induction period and subsequent anticancer therapy, death or discontinuation up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study
percentage of participantsNab-Paclitaxel + BSC: Induction + MaintenanceBSC: Induction + Maintenance
Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study69.1 (60.6 to 76.8)57.6 (44.8 to 69.7)
Statistical analysis
  • Nab-Paclitaxel + BSC: Induction + Maintenance vs BSC: Induction + Maintenance · Cochran-Mantel-Haenszel · p = 0.0870 (Stratification factors evaluated in the sparse strata elimination algorithm: stage of disease (IIIB or IV) at diagnosis, ECOG performance status (0 or 1) at the end of Induction, and tumor response (CR/PR or SD) at the end of Induction.) · Overall response rate ratio: 1.20 · 95% CI 0.948 to 1.519response ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryKaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study

PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression.

Time frame:
Between Day 1 of the Induction Part through to the date of disease progression or death; up to 01 August 2019; the maximum treatment duration was 234.1 weeks for entire study
Reported as:
Median · months
Kaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study
monthsNab-Paclitaxel + BSC: Induction + MaintenanceBSC: Induction + Maintenance
Kaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study6.47 (5.65 to 7.79)5.55 (4.96 to 6.67)
Statistical analysis
  • Nab-Paclitaxel + BSC: Induction + Maintenance vs BSC: Induction + Maintenance · stratified log-rank test · p = 0.4164 (Stratification factors evaluated in the sparse strata elimination algorithm: stage of disease (IIIB or IV) at diagnosis, ECOG performance status (0 or 1) at end of Induction, and tumor response (CR/PR or SD) at end of Induction.) · Hazard ratio (hr): 0.87 · 95% CI 0.62 to 1.22Hazard ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryKaplan-Meier Estimate of Overall Survival (OS) Over Entire Study

Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.

Time frame:
Between Day 1 of treatment in the Induction Part to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
Reported as:
Median · months
Kaplan-Meier Estimate of Overall Survival (OS) Over Entire Study
monthsNab-Paclitaxel + BSC: Induction + MaintenanceBSC: Induction + Maintenance
Kaplan-Meier Estimate of Overall Survival (OS) Over Entire Study20.57 (17.05 to 24.05)15.05 (10.81 to 22.14)
Statistical analysis
  • Nab-Paclitaxel + BSC: Induction + Maintenance vs BSC: Induction + Maintenance · stratified log-rank test · p = 0.0381 (Stratification factors evaluated in the sparse strata elimination algorithm: stage of disease (IIIB or IV) at diagnosis, ECOG performance status (0 or 1) at end of Induction, and tumor response (CR/PR or SD) at end of Induction.) · Hazard ratio (hr): 0.68 · 95% CI 0.47 to 0.98Hazard ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryPercentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction

Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease.

Time frame:
For the induction period the maximum treatment was 19 weeks for the maintenance period the maximum treatment was 150 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction
percentage of participantsNab-Paclitaxel + BSC: Induction + MaintenanceBSC: Induction + Maintenance
Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction9.6 (5.2 to 15.8)3.0 (0.4 to 10.5)
Statistical analysis
  • Nab-Paclitaxel + BSC: Induction + Maintenance vs BSC: Induction + Maintenance · Cochran-Mantel-Haenszel · p = 0.0978 (5% level of significance.) · Overall response rate ratio: 3.15 · 95% CI 0.733 to 13.574Response rate ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryPercentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study

Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for \>= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method.

Time frame:
Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 induction through maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study
percentage of participantsAll Participants - InductionNab-Paclitaxel + BSC: Induction + MaintenanceBSC: Induction + Maintenance
Percentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study47.9 (43.0 to 52.8)99.3 (96.0 to 100.0)100.0 (94.6 to 100.0)
Statistical analysis
  • Nab-Paclitaxel + BSC: Induction + Maintenance vs BSC: Induction + Maintenance · Disease control rate ratio: 0.99 · 95% CI 0.978 to 1.007Disease control rate ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryTime to Confirmed Response During Induction and Over the Entire Study

Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary.

Time frame:
Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 Induction through Maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
Reported as:
Median · months
Time to Confirmed Response During Induction and Over the Entire Study
monthsAll Participants - InductionNab-Paclitaxel + BSC: Induction + MaintenanceBSC: Induction + Maintenance
Time to Confirmed Response During Induction and Over the Entire Study1.446 (1.15 to 4.60)1.478 (1.15 to 8.51)1.413 (1.18 to 4.21)
SecondaryKaplan-Meier Estimate for Duration of Response Over the Entire Study

Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death.

Time frame:
Between Day 1 of the Induction Period through to the date of disease progression or death; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study.
Reported as:
Median · months
Kaplan-Meier Estimate for Duration of Response Over the Entire Study
monthsNab-Paclitaxel + BSC: Induction + MaintenanceBSC: Induction + Maintenance
Kaplan-Meier Estimate for Duration of Response Over the Entire Study5.95 (4.60 to 7.06)4.60 (3.68 to 5.49)
Statistical analysis
  • Nab-Paclitaxel + BSC: Induction + Maintenance vs BSC: Induction + Maintenance · Hazard ratio (hr): 0.93 · 95% CI 0.59 to 1.47Hazard ratio: nab-paclitaxel + BSC / BSC Alone
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAEs) in the Induction Period

TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.

Time frame:
Day 1 of Induction up to Week 23 (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance)
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events (TEAEs) in the Induction Period
ParticipantsAll Participants - InductionTEAE Specific to Nab-PaclitaxelTEAE Specific to Carboplatin
TEAE419NANA
Serious TEAE177NANA
Severity Grade 3/4 TEAE337NANA
Severity Grade 3 or higher TEAE340NANA
Treatment-related (trt-related) TEAE408407394
Trt-related serious TEAE828073
TEAE-study drug dose reduced or interrupted341340291
Trt-related TEAE-dose reduced or interrupted301292236
TEAE-study drug withdrawn555553
Trt-related TEAE-study drug withdrawn353429
TEAE-outcome of death32NANA
Trt-related TEAE-outcome of death776
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAEs) Over the Entire Study

TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.

Time frame:
From Day 1 up to 01 August 2019; (maximum treatment length plus 28 days); the maximum treatment duration was 234.1 weeks for entire study
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events (TEAEs) Over the Entire Study
ParticipantsNab-Paclitaxel + BSC: Induction + MaintenanceNab-Paclitaxel + BSC: TEAE Specific to Nab-PaclitaxelNab-Paclitaxel + BSC: TEAE Specific to CarboplatinNab-Paclitaxel + BSC: TEAE Specific to BSCBSC: Induction + MaintenanceBSC: TEAE Specific to Nab-PaclitaxelBSC: TEAE Specific to CarboplatinBSC: TEAE Specific to BSC
TEAE130NANANA62NANANA
Serious TEAE54NANANA21NANANA
Severity Grade 3/4 TEAE108NANANA48NANANA
Severity Grade 3 or higher TEAE109NANANA48NANANA
Treatment-related (trt-related) TEAE129129123186161581
Trt-related serious TEAE22221618870
TEAE-study drug dose reduced or interrupted11511395175252451
Trt-related TEAE-dose reduced or interrupted1071048504545370
TEAE-study drug withdrawn22221200110
Trt-related TEAE- study drug withdrawn1818121000
TEAE-outcome of death4NANANA2NANANA
Trt-related TEAE-outcome of death00000000

Adverse events

Collected over 1. All Participants - Induction: Day 1 up to 23 weeks (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance) 2. Nab-Paclitaxel + Best Supportive Care (BSC): Randomization into Maintenance up to 154 weeks (maximum treatment in Maintenance plus 4 weeks) 3. Best Supportive Care (BSC): Randomization into Maintenance up to 120 weeks (maximum treatment in Maintenance plus 4 weeks) TEAEs are reported up to the data cut off date of 01 August 2019.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants - Induction80/420 (19%)177/420 (42.1%)417/420 (99.3%)
Nab-Paclitaxel + Best Supportive Care (Maintenance)82/130 (63.1%)32/130 (24.6%)122/130 (93.8%)
Best Supportive Care (Maintenance)48/62 (77.4%)13/62 (21%)45/62 (72.6%)
Most frequent serious events
Showing 10 of 161
Most frequent serious events
EventAll Participants - InductionNab-Paclitaxel + Best Supportive Care (Maintenance)Best Supportive Care (Maintenance)
PneumoniaInfections and infestations24/4204/1303/62
AnaemiaBlood and lymphatic system disorders17/4203/1300/62
DyspnoeaRespiratory, thoracic and mediastinal disorders15/4200/1300/62
DehydrationMetabolism and nutrition disorders14/4201/1300/62
General physical health deteriorationGeneral disorders4/4200/1302/62
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders7/4200/1302/62
NeutropeniaBlood and lymphatic system disorders12/4200/1300/62
DiarrhoeaGastrointestinal disorders11/4201/1301/62
HypotensionVascular disorders11/4200/1300/62
AstheniaGeneral disorders6/4203/1300/62
Most frequent other events
Showing 10 of 49
Most frequent other events
EventAll Participants - InductionNab-Paclitaxel + Best Supportive Care (Maintenance)Best Supportive Care (Maintenance)
AnaemiaBlood and lymphatic system disorders256/42024/1306/62
NeutropeniaBlood and lymphatic system disorders225/42014/1300/62
NauseaGastrointestinal disorders191/42016/1302/62
Peripheral sensory neuropathyNervous system disorders152/42056/1306/62
FatigueGeneral disorders175/42024/1300/62
ThrombocytopeniaBlood and lymphatic system disorders163/4209/1302/62
DiarrhoeaGastrointestinal disorders158/42018/1304/62
ConstipationGastrointestinal disorders130/42014/1300/62
AlopeciaSkin and subcutaneous tissue disorders105/4206/1302/62
Decreased appetiteMetabolism and nutrition disorders101/42017/1303/62

Baseline characteristics

Induction includes participants who were enrolled and treated however, baseline characteristics (BLC) for non-randomised participants is not displayed. The total number represents the ITT population in the maintenance phase.

Age, Continuous
Age, Continuous(years)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
Mean67.1 ± 9.0266.8 ± 8.0667.0 ± 8.70
Age, Customized
Age, Customized(Participants)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
<65 years482775
>=65 years8839127
<70 years7941120
>=70 years572582
<75 years11055165
>=75 years261137
Sex: Female, Male
Sex: Female, Male(Participants)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
Female492372
Male8743130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
Hispanic or Latino358
Not Hispanic or Latino13261193
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
American Indian or Alaska Native101
Asian101
Black or African American9211
White12562187
Other022
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
0=fully active, no restriction411960
1=fully ambulatory; restricted strenuous activity9547142
>=2=ambulatory/self care; no work or worse000
Overall Tumor Response at End of Induction
Overall Tumor Response at End of Induction(Participants)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
Complete response123
Partial response9242134
Stable disease412162
Progressive disease202
Not evaluable011
Confirmed Histology
Confirmed Histology(Participants)Nab-Paclitaxel + Best Supportive Care (BSC)Best Supportive Care (BSC)Total
Squamous cell carcinoma13666202
Squamous cell carcinoma not confirmed000

1 further baseline measures are reported on the registry.

08

Study locations

119 sites
  • Clearview Cancer Institute Oncology Specialties, P.C
    Huntsville, Alabama 35805, United States
  • Palo Verde Hematology Oncology, Ltd.
    Glendale, Arizona 85304, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85715, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • City of Hope Cancer Center
    Duarte, California 91010-3000, United States
  • Cancer Care Associates of Fresno Medical Group Inc
    Fresno, California 93720, United States
  • University of California San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Clinical Trials and Research Associates
    Montebello, California 90640, United States
  • VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80218, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Watson Clinic, LLP Center for Cancer Care and Research
    Lakeland, Florida 33805, United States
  • University of Miami Miller School of Medicine Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Memorial Cancer Institute West
    Pembroke Pines, Florida 33028, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University Cancer and Blood Center, LLC
    Athens, Georgia 30607, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Joliet Oncology-Hematology Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Indiana University Medical Center
    Indianapolis, Indiana 46202-5149, United States
  • Investigative Clinical Research of Indiana, LLC
    Indianapolis, Indiana 46260, United States
  • Kansas University Medical Center
    Westwood, Kansas 66205, United States
  • Cancer Center of Kansas (MAT)
    Wichita, Kansas 67208, United States
  • Kentucky Cancer Clinic
    Hazard, Kentucky 41701, United States
  • Norton Healthcare
    Louisville, Kentucky 40202, United States
  • University of Louisville, J.G. Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Norton Cancer Institute Louisville Oncology
    Louisville, Kentucky 40207, United States
  • LSU Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Maine Research Associates
    Auburn, Maine 04210, United States
  • Eastern Maine Medical Center
    Brewer, Maine 04412, United States
  • Center For Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Meritus Medical Center
    Hagerstown, Maryland 21742, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Detroit Clinical Research Center
    Farmington Hills, Michigan 48334, United States
  • Western Michigan Cancer Center
    Kalamazoo, Michigan 49007, United States
  • St Joseph Oncology
    Saint Joseph, Missouri 64507, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Mercy Medical Research Institute
    Springfield, Missouri 65804, United States
  • Englewood Hospital and Medical Center
    Englewood, New Jersey 07631, United States
  • Hematology-Oncology Associates of NNJ, P
    Morristown, New Jersey 07960, United States
  • New York Oncology Hematology P.C.
    Albany, New York 12206, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center Albert Einstein Cancer Center
    Bronx, New York 10467, United States
  • Clinical Research Alliance
    Lake Success, New York 11042, United States
  • NYU Langone Medical Center
    Lake Success, New York 11042, United States
  • Beth Israel Medical Centers
    New York, New York 10003, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai Medical Center
    New York, New York 10029, United States
  • Rochester General Hospital
    Rochester, New York 14621, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
  • Southeastern Medical Oncology Center
    Goldsboro, North Carolina 27534, United States
  • Moses H. Cone Regional Cancer Center
    Greensboro, North Carolina 27403, United States
  • Hematology and Oncology Associates, Inc.
    Canton, Ohio 44708, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • The Mark H. Zangmeister Center
    Columbus, Ohio 43219, United States
  • Tri-County Hematology and Oncology Associates
    Massillon, Ohio 44646, United States
  • Toledo Community Oncology Program
    Toledo, Ohio 43623, United States
  • Mercy Clinic Oklahoma Communities, Inc.
    Oklahoma City, Oklahoma 73102, United States
  • University of Oklahoma Peggy and Charles Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Erie Regional Cancer Center
    Erie, Pennsylvania 16505, United States
  • Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • University of Pennsylvania Health Systems
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny Singer Research Institute
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center - Cancer Pavilion
    Pittsburgh, Pennsylvania 15232, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Chattanooga Oncology Hematology Care
    Chattanooga, Tennessee 37404, United States
  • Associates in Oncology and Hematology
    Chattanooga, Tennessee 37421, United States
  • Thompson Cancer Survival Center
    Knoxville, Tennessee 37916, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203-1632, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • TX Onc, PA- Beaumont
    Beaumont, Texas 77702-1449, United States
  • Brooke Army Medical Center Francis Street Medical Center
    Fort Sam Houston, Texas 78235-8200, United States
  • Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • UT Health Oncology
    Houston, Texas 77030, United States
  • Millenium Oncology
    Houston, Texas 77090, United States
  • TX Onc Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Columbia Basin Hematology and Oncology
    Kennewick, Washington 99336, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • St Mary's Medical Center
    Huntington, West Virginia 25702, United States
  • West Virginia University, Berkeley Medical Center, Cancer and Infusion Center
    Martinsburg, West Virginia 25401, United States
  • West Virginia University, Berkeley Medical Center, Cancer and Infusion Center
    Morgantown, West Virginia 26506, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • St. Antonius Hospital
    Eschweiler, 52249, Germany
  • Asklepios Fachkliniken Muenchen Gauting
    Gauting, 82131, Germany
  • Diakoniekrankenhaus Halle
    Halle (Saale), 6114, Germany
  • Universitatsklinikum Halle Saale
    Halle, 06120, Germany
  • Thorax Klinik
    Heidelberg, 69126, Germany
  • Universitat Des Saarlandes
    Homburg, 66421, Germany
  • Kliniken der Stadt Koln gGmbH - Krankenhaus Merheim
    Koln, 51109, Germany
  • Klinik Loewenstein gGmbH
    Loewenstein, 74245, Germany
  • Lungenklinik Lostau gGmbH
    Lostau, 39291, Germany

Showing the first 100 of 119 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C. nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. Lung Cancer (Auckl). 2017 Oct 30;8:207-216. doi: 10.2147/LCTT.S138570. eCollection 2017. PubMed 29138610 ↗
  • Mudad R, Patel MB, Margunato-Debay S, Garofalo D, Lal LS. Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. Lung Cancer (Auckl). 2017 Oct 19;8:179-190. doi: 10.2147/LCTT.S139647. eCollection 2017. PubMed 29089791 ↗
  • Reni M, Zanon S, Balzano G, Passoni P, Pircher C, Chiaravalli M, Fugazza C, Ceraulo D, Nicoletti R, Arcidiacono PG, Macchini M, Peretti U, Castoldi R, Doglioni C, Falconi M, Partelli S, Gianni L. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018 Oct;102:95-102. doi: 10.1016/j.ejca.2018.07.007. Epub 2018 Aug 24. PubMed 30149366 ↗
  • Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Gluck S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201. PubMed 29878040 ↗
  • Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. Clin Ther. 2019 Mar;41(3):477-493.e7. doi: 10.1016/j.clinthera.2019.01.009. Epub 2019 Feb 14. PubMed 30773308 ↗
  • Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Adv Ther. 2018 Oct;35(10):1564-1577. doi: 10.1007/s12325-018-0784-z. Epub 2018 Sep 12. PubMed 30209750 ↗
  • Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B, Murphy B, Hackman T, Liao JJ, Grilley Olson J, Hayes DN. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncol. 2018 Sep;84:46-51. doi: 10.1016/j.oraloncology.2018.06.028. Epub 2018 Jul 19. PubMed 30115475 ↗
  • Li F, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai MP, Yuan H, Sun D. Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles. Mol Pharm. 2018 Oct 1;15(10):4505-4516. doi: 10.1021/acs.molpharmaceut.8b00527. Epub 2018 Sep 21. PubMed 30180593 ↗
  • Pelzer U, Wislocka L, Juhling A, Striefler J, Klein F, Roemmler-Zehrer J, Sinn M, Denecke T, Bahra M, Riess H. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis. Eur J Cancer. 2018 Sep;100:85-93. doi: 10.1016/j.ejca.2018.06.001. Epub 2018 Jul 4. PubMed 30014884 ↗
  • Metts JL, Alazraki AL, Clark D, Amankwah EK, Wasilewski-Masker KJ, George BA, Olson TA, Cash T. Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas. Pediatr Blood Cancer. 2018 Sep;65(9):e27246. doi: 10.1002/pbc.27246. Epub 2018 May 17. PubMed 29770997 ↗
  • Langer CJ, Kim ES, Anderson EC, Jotte RM, Modiano M, Haggstrom DE, Socoteanu MP, Smith DA, Dakhil C, Konduri K, Berry T, Ong TJ, Sanford A, Amiri K, Goldman JW, Weiss J; ABOUND.70+ Investigators. nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Front Oncol. 2018 Jul 24;8:262. doi: 10.3389/fonc.2018.00262. eCollection 2018. PubMed 30087851 ↗
  • Gajra A, Karim NA, Mulford DA, Villaruz LC, Matrana MR, Ali HY, Santos ES, Berry T, Ong TJ, Sanford A, Amiri K, Spigel DR. nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2. Front Oncol. 2018 Jul 24;8:253. doi: 10.3389/fonc.2018.00253. eCollection 2018. PubMed 30087850 ↗
  • Cartwright TH, Parisi M, Espirito JL, Wilson TW, Pelletier C, Patel M, Babiker HM. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs Real World Outcomes. 2018 Sep;5(3):149-159. doi: 10.1007/s40801-018-0137-x. PubMed 29946913 ↗
  • Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcon S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21. PubMed 29936064 ↗
  • Young R, Mainwaring P, Clingan P, Parnis FX, Asghari G, Beale P, Aly A, Botteman M, Romano A, Ferrara S, Margunato-Debay S, Harris M. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Asia Pac J Clin Oncol. 2018 Oct;14(5):e325-e331. doi: 10.1111/ajco.12999. Epub 2018 Jun 22. PubMed 29932294 ↗
  • Topcul M, Ceti N IL, Ozbas Turan S, Kolusayin Ozar MO. In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells. Oncol Rep. 2018 Jul;40(1):527-535. doi: 10.3892/or.2018.6364. Epub 2018 Apr 12. PubMed 29658592 ↗
  • Neumann CCM, von Horschelmann E, Reutzel-Selke A, Seidel E, Sauer IM, Pratschke J, Bahra M, Schmuck RB. Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):461-472. doi: 10.1016/j.hbpd.2018.09.004. Epub 2018 Sep 7. PubMed 30243879 ↗
  • Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9. PubMed 30442938 ↗
  • Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1. PubMed 30383906 ↗
  • Marschner N, Salat C, Soling U, Hansen R, Grebhardt S, Harde J, Nusch A, Potthoff K. Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel. Clin Breast Cancer. 2018 Dec;18(6):e1323-e1337. doi: 10.1016/j.clbc.2018.07.010. Epub 2018 Aug 10. PubMed 30100104 ↗
  • Watson S, de la Fouchardiere C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet C. Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). Eur J Cancer. 2019 Jan;107:46-52. doi: 10.1016/j.ejca.2018.11.006. Epub 2018 Dec 7. Erratum In: Eur J Cancer. 2019 Sep;118:190. doi: 10.1016/j.ejca.2019.06.004. PubMed 30529902 ↗
  • Li YF, Zhang C, Zhou S, He M, Zhang H, Chen N, Li F, Luan X, Pai M, Yuan H, Sun D, Li Y. Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. Clin Pharmacol. 2018 Nov 8;10:165-174. doi: 10.2147/CPAA.S185449. eCollection 2018. PubMed 30519122 ↗
  • Hurria A, Soto-Perez-de-Celis E, Blanchard S, Burhenn P, Yeon CH, Yuan Y, Li D, Katheria V, Waisman JR, Luu TH, Somlo G, Noonan AM, Lee T, Sudan N, Chung S, Rotter A, Arsenyan A, Levi A, Choi J, Rubalcava A, Morrison R, Mortimer JE. A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology. Clin Breast Cancer. 2019 Apr;19(2):89-96. doi: 10.1016/j.clbc.2018.10.002. Epub 2018 Oct 16. PubMed 30503309 ↗
  • Fernandez A, Salgado M, Garcia A, Buxo E, Vera R, Adeva J, Jimenez-Fonseca P, Quintero G, Llorca C, Canabate M, Lopez LJ, Munoz A, Ramirez P, Gonzalez P, Lopez C, Reboredo M, Gallardo E, Sanchez-Canovas M, Gallego J, Guillen C, Ruiz-Miravet N, Navarro-Perez V, De la Camara J, Ales-Diaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3. PubMed 30497432 ↗
  • Awasthi N, Schwarz MA, Zhang C, Schwarz RE. Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models. Mol Cancer Ther. 2018 Nov;17(11):2353-2364. doi: 10.1158/1535-7163.MCT-18-0489. Epub 2018 Aug 30. PubMed 30166402 ↗
  • Nakao A, Uchino J, Igata F, On R, Ikeda T, Yatsugi H, Hirano R, Sasaki T, Tanimura K, Imabayashi T, Tamiya N, Kaneko Y, Yamada T, Nagata N, Watanabe K, Kishimoto J, Takayama K, Fujita M. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naive patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. Invest New Drugs. 2018 Oct;36(5):903-910. doi: 10.1007/s10637-018-0617-6. Epub 2018 May 30. PubMed 29846848 ↗
  • Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Carroll M, Prakash N, Dellinger T, Park M, Morgan RJ. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol. 2019 Mar;83(3):589-598. doi: 10.1007/s00280-019-03767-9. Epub 2019 Jan 8. PubMed 30623229 ↗
  • Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, Janicke M, Marschner N; TPK-Group (Tumour Registry Pancreatic Cancer). Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer. 2019 Mar 1;144(5):981-990. doi: 10.1002/ijc.31751. Epub 2018 Oct 3. PubMed 30006989 ↗
  • Wang Z, Huang C, Yang JJ, Song Y, Cheng Y, Chen GY, Yan HH, Ben XS, Wang BC, Xu CR, Jiang BY, Zhou Q, Chen HJ, Wu YL. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). Eur J Cancer. 2019 Mar;109:183-191. doi: 10.1016/j.ejca.2019.01.007. Epub 2019 Feb 7. PubMed 30739019 ↗
  • Woo W, Carey ET, Choi M. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives. Onco Targets Ther. 2019 Feb 21;12:1455-1463. doi: 10.2147/OTT.S167590. eCollection 2019. PubMed 30863113 ↗
  • Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522. Erratum In: Ann Oncol. 2019 Oct 1;30(10):1673. doi: 10.1093/annonc/mdz171. PubMed 30481287 ↗
  • De Luca R, Profita G, Cicero G. Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life. Onco Targets Ther. 2019 Feb 26;12:1621-1627. doi: 10.2147/OTT.S191519. eCollection 2019. PubMed 30881017 ↗
  • Morgensztern D, Ko A, O'Brien M, Ong TJ, Waqar SN, Socinski MA, Postmus PE, Bhore R. Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy. Cancer. 2019 Jul 15;125(14):2394-2399. doi: 10.1002/cncr.32114. Epub 2019 Apr 1. PubMed 30933354 ↗
  • Li F, Yuan H, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai M, Sun D. Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. Mol Pharm. 2019 Jun 3;16(6):2385-2393. doi: 10.1021/acs.molpharmaceut.8b01314. Epub 2019 May 1. PubMed 31002261 ↗
  • Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, Reni M, Li CP, O'Neil B, Van Cutsem E, Bekaii-Saab T. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019 Apr;15(12):1295-1302. doi: 10.2217/fon-2018-0903. Epub 2019 Feb 15. PubMed 30768369 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Sep 2017, 43 months.

Results were first posted in Dec 2018, 1 year 2 months after primary completion.

Of 21 phase 3 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 91. This study's 43 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2014
First posted
Jan 6, 2014
StartActual
Feb 11, 2014
Primary completionActual
Sep 15, 2017
CompletionActual
Aug 1, 2019
Results first posted
Dec 7, 2018
Last update
Aug 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02027428
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 6, 2014
Start date
Feb 11, 2014
Primary completion
Sep 15, 2017
Completion
Aug 1, 2019
Results posted
Dec 7, 2018
Last update
Aug 17, 2020

Study contacts

Teng Jin Ong, MD
study director · Celgene

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion